GlassScriptPhysician profile
James Y Rhee
NPI 1033105531
$7,458.50
in general payments reported to CMS, 2019-2025
39 companies · $1,314 in 2025
The $1,314 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $987 · 2020: $345 · 2021: $1,201 · 2022: $1,258 · 2023: $1,096 · 2024: $1,258 · 2025: $1,314.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,531 · Education: $74.75 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $62.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,530.82 |
| Education | $74.75 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $62.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,044.13 | 2019-2025 | |
| Gilead Sciences, INC. | $837.54 | 2019-2025 | |
| Janssen Biotech, INC. | $756.54 | 2019-2025 | Stelara, Tremfya, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $517.45 | 2019-2025 | Xifaxan, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $498.13 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Celgene Corporation | $487.09 | 2021-2024 | Zeposia |
| Pfizer INC. | $293.25 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $256.21 | 2022-2025 | Dupixent |
| Allergan, INC. | $239.46 | 2019-2020 | |
| Genzyme Corporation | $181.72 | 2023-2025 | |
| Madrigal Pharmaceuticals | $151.23 | 2024-2025 | Rezdiffra, Resmetirom |
| Lilly USA, LLC | $137.14 | 2024-2025 | Omvoh |
| Ipsen Biopharmaceuticals, INC | $114.94 | 2024-2025 | Iqirvo |
| Intercept Pharmaceuticals, INC. | $108.00 | 2019-2025 | |
| Eisai INC. | $77.19 | 2021 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Rhee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.